Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CDA | P32320 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 3/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | UMPS | P11172 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6790406 | 1.00 | HIF1A (0.41) | HIF1ASLC5A2ALDH1A1MAPTCDA | |
| SCHEMBL6784255 | 0.78 | SLC5A2 (0.50) | HIF1ASLC5A2MAPTCDAPYGL | |
| SCHEMBL6790225 | 0.78 | HIF1A (0.43) | HIF1ASLC5A2MAPTCDAPYGL | |
| SCHEMBL6790150 | 0.78 | HIF1A (0.43) | HIF1ASLC5A2MAPTCDAPYGL | |
| SCHEMBL6785624 | 0.78 | HIF1A (0.43) | HIF1ASLC5A2MAPTCDAPYGL | |
| SCHEMBL6790684 | 0.78 | SLC5A2 (0.50) | HIF1ASLC5A2MAPTCDAPYGL | |
| SCHEMBL6790218 | 0.78 | HIF1A (0.43) | HIF1ASLC5A2MAPTCDAPYGL | |
| SCHEMBL6784647 | 0.78 | MAPT (0.40) | SLC5A2ALDH1A1MAPTCDAPYGL | |
| SCHEMBL6784652 | 0.78 | MAPT (0.40) | SLC5A2ALDH1A1MAPTCDAPYGL | |
| SCHEMBL4875548 | 0.76 | ADK (0.43) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | PHARMASSET, INC. | 2004-12-30 | — | — | US | disclosed |
| CN-1527836-A | Antiviral agents for treatment of flaviviridae infections | — | 2004-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266723-A1 | Antiviral agents for treatment of Flaviviridae infections | HAVCR2, MAVS, EIF2AK2 | HIF1A 3985/4885SLC5A2 309/4885ALDH1A1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.